Acalabrutinib Shows Better Exposure-Adjusted Tolerability in R/R CLL
June 2nd 2022John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.